FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212041674> ?p ?o ?g. }

• W3212041674 endingPage "A480" @default.
• W3212041674 startingPage "A479" @default.
• W3212041674 abstract "Background Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of PLC management at all evolutionary stages. 1 As an anti-programmed cell death-1 (PD-1) antibody, camrelizumab monotherapy and in combination with apatinib, an anti-angiogenetic tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-2, chemotherapy or locoregional therapy, have demonstrated their efficacy in advanced hepatocellular carcinoma (HCC). 2 3 4 5 Methods This prospective, open-label, multi-center, observational RWS was conducted to evaluate efficacy and safety of camrelizumab in treatment of PLC in clinical practice. Eligible patients were histopathologically or cytologically identified HCC or intrahepatic cholangiocarcinoma, who were going to receive camrelizumab treatment, with age ≥18 ages, Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0–2 and Child-Pugh score ≤ 9. Patients were treated at clinician discretion. Three hundred patients were planned to enroll, including advanced or peri-operative PLC. The primary endpoint was progress-free survival for advanced PLC, whose efficacy was available to analysis. Efficacy was assessed per Response Evaluation Criteria in Solid Tumors version 1.1. Results From March 29, 2020 to June 10, 2021,a total of 147 eligible patients of advanced PLC were enrolled and included in this interim analysis, with 128 (87.1%) men, 130 (94.9%) ECOG PS of 0–1, 139 (94.6%) HCC, 74 (50.4%) Barcelona Clinic Liver Cancer stage C, 98 (66.7%) Child-Pugh B, and 72 (49.0%) with extrahepatic metastases, shown in table 1. Of the 147 patients, 45 (30.1%) patients were treated with camrelizumab monotherapy, 79 (53.8%) patients with combination with angiogenesis inhibitors, of which 55 (37.4%) in combination with apatinib, 21 (14.3%) patients with camrelizumab and chemotherapy. Patients, who had at least one efficacy assessment, were included in the efficacy analyses. Up to July 19, 2021, with a median follow time of 6.2 months, 132 patients were available for efficacy analyses. Patient disposition was shown in figure 1. Objective response rate (ORR) and disease control rate (DCR) were 10%/30.8%/35.3% and 75.0%/86.5%/70.6% in camrelizumab monotherapy/combined with apatinib/combined with chemotherapy, respectively. (table 2) The most common camrelizumab-treatment related adverse events (AEs) included reactive cutaneous capillary endothelial proliferation (RCCEP) (12, 8.2%), ICI-induced pneumonia (2, 1.4%), enterocolitis (2, 1.4%), and nephritis (1, 0.7%), of which all these AEs recovered. Other AEs included increase of transaminase (5, 3.4%) and hypertension (4, 2.7%). All AEs were 1–2 grade and no treatment-related death occurred. Abstract 452 Table 1 Baseline characteristics Abstract 452 Figure 1 Patient disposition Abstract 452 Table 2 Confirmed tumor response assessed by investigators per RECIST v1.1 Conclusions Camrelizumab, combined with anti-angiogenetic agents or chemotherapy, or monotherapy, demonstrated good efficacy and safety in treatment of PLC. Trial Registration ChiCTR2000034264 References Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7 (1):6–28. Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020; 21 (4):571–580. Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res 2021; 27 (4):1003–1011. Mei K, Qin S, Chen Z, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer 2021; 9 (3). Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31 (28):3501–3508. Ethics Approval This study was approved by China registered clinical trial ethics review committee with No.ChiECRCT20200042." @default.
• W3212041674 created "2021-11-22" @default.
• W3212041674 creator A5003205988 @default.
• W3212041674 creator A5003568288 @default.
• W3212041674 creator A5005700142 @default.
• W3212041674 creator A5032402468 @default.
• W3212041674 creator A5066685111 @default.
• W3212041674 creator A5070903685 @default.
• W3212041674 creator A5076731937 @default.
• W3212041674 creator A5079045731 @default.
• W3212041674 creator A5084792906 @default.
• W3212041674 creator A5090133389 @default.
• W3212041674 date "2021-11-01" @default.
• W3212041674 modified "2023-09-26" @default.
• W3212041674 title "452 Preliminary analysis of a real-world study (RWS) of camrelizumab treatment in primary liver cancer (PLC)" @default.
• W3212041674 doi "https://doi.org/10.1136/jitc-2021-sitc2021.452" @default.
• W3212041674 hasPublicationYear "2021" @default.
• W3212041674 type Work @default.
• W3212041674 sameAs 3212041674 @default.
• W3212041674 citedByCount "0" @default.
• W3212041674 crossrefType "journal-article" @default.
• W3212041674 hasAuthorship W3212041674A5003205988 @default.
• W3212041674 hasAuthorship W3212041674A5003568288 @default.
• W3212041674 hasAuthorship W3212041674A5005700142 @default.
• W3212041674 hasAuthorship W3212041674A5032402468 @default.
• W3212041674 hasAuthorship W3212041674A5066685111 @default.
• W3212041674 hasAuthorship W3212041674A5070903685 @default.
• W3212041674 hasAuthorship W3212041674A5076731937 @default.
• W3212041674 hasAuthorship W3212041674A5079045731 @default.
• W3212041674 hasAuthorship W3212041674A5084792906 @default.
• W3212041674 hasAuthorship W3212041674A5090133389 @default.
• W3212041674 hasBestOaLocation W32120416741 @default.
• W3212041674 hasConcept C121608353 @default.
• W3212041674 hasConcept C126322002 @default.
• W3212041674 hasConcept C143998085 @default.
• W3212041674 hasConcept C203092338 @default.
• W3212041674 hasConcept C2776694085 @default.
• W3212041674 hasConcept C2776999253 @default.
• W3212041674 hasConcept C2777802072 @default.
• W3212041674 hasConcept C2778019345 @default.
• W3212041674 hasConcept C2780668389 @default.
• W3212041674 hasConcept C2780739268 @default.
• W3212041674 hasConcept C535046627 @default.
• W3212041674 hasConcept C61943457 @default.
• W3212041674 hasConcept C71924100 @default.
• W3212041674 hasConceptScore W3212041674C121608353 @default.
• W3212041674 hasConceptScore W3212041674C126322002 @default.
• W3212041674 hasConceptScore W3212041674C143998085 @default.
• W3212041674 hasConceptScore W3212041674C203092338 @default.
• W3212041674 hasConceptScore W3212041674C2776694085 @default.
• W3212041674 hasConceptScore W3212041674C2776999253 @default.
• W3212041674 hasConceptScore W3212041674C2777802072 @default.
• W3212041674 hasConceptScore W3212041674C2778019345 @default.
• W3212041674 hasConceptScore W3212041674C2780668389 @default.
• W3212041674 hasConceptScore W3212041674C2780739268 @default.
• W3212041674 hasConceptScore W3212041674C535046627 @default.
• W3212041674 hasConceptScore W3212041674C61943457 @default.
• W3212041674 hasConceptScore W3212041674C71924100 @default.
• W3212041674 hasIssue "Suppl 3" @default.
• W3212041674 hasLocation W32120416741 @default.
• W3212041674 hasLocation W32120416742 @default.
• W3212041674 hasOpenAccess W3212041674 @default.
• W3212041674 hasPrimaryLocation W32120416741 @default.
• W3212041674 hasRelatedWork W1965325738 @default.
• W3212041674 hasRelatedWork W1997961771 @default.
• W3212041674 hasRelatedWork W2329621221 @default.
• W3212041674 hasRelatedWork W2680183591 @default.
• W3212041674 hasRelatedWork W2899140013 @default.
• W3212041674 hasRelatedWork W2955181235 @default.
• W3212041674 hasRelatedWork W2981773923 @default.
• W3212041674 hasRelatedWork W3004966710 @default.
• W3212041674 hasRelatedWork W3137351398 @default.
• W3212041674 hasRelatedWork W3198049980 @default.
• W3212041674 hasVolume "9" @default.
• W3212041674 isParatext "false" @default.
• W3212041674 isRetracted "false" @default.
• W3212041674 magId "3212041674" @default.
• W3212041674 workType "article" @default.